Showing results (61-70 of 224) with videos related to
Sort By:
Pageof 23
Kidney International|February 2, 2025
Treatment of patients with IgA nephropathy: a call for a new paradigmJürgen Floege, Amelie Bernier-Jean, Jonathan Barratt, et al.Therapeutic Advances in Rare Disease|July 22, 2025
Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT studyBrad H Rovin, Radko Komers, Chris Scroggins, et al.Kidney International|March 25, 2019
IgA nephropathy: "State of the art": a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first descriptionHernán Trimarchi, Jonathan Barratt, Renato C Monteiro, et al.Seminars in Immunopathology|September 14, 2007
Immunopathogenesis of IgANJonathan Barratt, Alice C Smith, Karen Molyneux, et al.Journal of Nephrology|November 20, 2024
Post-transplant IgA nephropathy: a rapidly evolving field of kidney transplant medicineMehmet Kanbay, Lasin Ozbek, Mustafa Guldan, et al.Seminars in Nephrology|September 5, 2018
Aberrant Glycosylation of the IgA1 Molecule in IgA NephropathyJan Novak, Jonathan Barratt, Bruce A Julian, et al.Contributions to Nephrology|May 15, 2007
International IgA nephropathy network clinico-pathological classification of IgA nephropathyJohn Feehally, Jonathan Barratt, Rosanna Coppo, et al.Pharmaceutical Statistics|November 3, 2023
Conditional power and information fraction calculations at an interim analysis for random coefficient modelsSandra A Lewis, Kevin J Carroll, Todd DeVries, et al.Expert Review of Clinical Immunology|April 27, 2023
Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathyJonathan Barratt, Richard A Lafayette, Brad H Rovin, et al.The New England Journal of Medicine|November 10, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 TrialVlado Perkovic, Hernán Trimarchi, Vladimir Tesar, et al.Pageof 23